Objective: To summarize the current knowledge on the therapeutic potential of GLP-1 receptor agonists in managing metabolic associated steatotic liver disease (MASLD).
Data Sources: A literature review was conducted using the search terms , , , , , and on PubMed (from January 1, 2019, through February 1, 2025), National Institutes of Health (NIH) (from January 1, 2019, through February 1, 2025), Scopus (from January 1, 2019, through February 1, 2025), and the World Health Organization (WHO) data.
Study Selection And Data Extraction: All relevant clinical trials, review articles, package inserts, and guidelines evaluating clinically relevant evidence regarding the therapeutic potential of GLP-1 agonists in MASLD were considered for inclusion.
Data Synthesis: GLP-1 RAs have shown promising results in MASLD treatment. Semaglutide has demonstrated efficacy in reducing liver fat content, inflammation, and fibrosis, with clinical trials indicating improvements in hepatic biomarkers and cardiometabolic risk factors. Similarly, tirzepatide has been associated with substantial weight loss and significant reductions in liver fat and fibrosis markers. Both agents exert their effects through mechanisms involving improved insulin sensitivity, reduced lipid accumulation, and attenuation of hepatic inflammation.
Relevance To Patient Care And Clinical Practice: Given the high prevalence of MASLD in patients with obesity and type 2 diabetes, tirzepatide and semaglutide could play a critical role in clinical practice by addressing multiple facets of the disease. Both agents have shown potential in reducing liver fat, improving hepatic biomarkers, and mitigating cardiometabolic risks, which are leading causes of morbidity and mortality in MASLD patients. Incorporating these therapies into MASLD treatment guidelines could significantly enhance patient outcomes by targeting both liver-related and systemic complications of the disease.
Conclusions: GLP1 RAs show great potential in managing MASLD by promoting weight loss, improving glycemic control, and reducing liver inflammation.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1177/10600280251322002 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
In Vivo Behavior of Transitional Foods as Compared to Purees: A Videofluoroscopic Analysis.
Am J Speech Lang Pathol
March 2025
Communication Disorders and Sciences, University of Oregon, Eugene.
Purpose: Medically tailored transitional foods (TFs) may be a clinically viable alternative to pureed consistency for individuals requiring texture-modified foods. However, little remains known about the performance of TFs during the swallow. The purpose of this investigation was to describe oropharyngeal swallowing physiology in patients with dysphagia during consumption of TFs as compared to pureed solids.
View Article and Find Full Text PDFInflammatory Microenvironment-Modulated Conductive Hydrogel Promotes Vascularized Bone Regeneration in Infected Bone Defects.
ACS Biomater Sci Eng
March 2025
College of Stomatology, Chongqing Medical University, 426 Songshibei Road, Yubei District, Chongqing 401147, China.
Infected bone defects show a significant reduction in neovascularization during the healing process, primarily due to persistent bacterial infection and immune microenvironmental disorders. Existing treatments are difficult to simultaneously meet the requirements of antibacterial and anti-inflammatory treatments for infected bone defects, which is a key clinical therapeutic challenge that needs to be addressed. In this study, a conductive hydrogel based on copper nanoparticles was developed for controlling bacterial infection and remodeling the immune microenvironment.
View Article and Find Full Text PDFEffects of PARP1 inhibitor PJ-34 on TGFα, IL-6, and IL-1β levels in diabetic nephropathy.
J Immunol
February 2025
Orthopedics Department, Central Hospital of Ezhou, Ezhou, China.
Diabetic nephropathy is a severe chronic complication characterized by cytotoxicity, inflammation, and fibrosis, ultimately leading to renal failure. This study systematically investigated the effects of the PARP1 inhibitor PJ-34 on high glucose-induced cytotoxicity, inflammation, and fibrosis in HK-2 cells, as well as its improvement on neuropathic pain response and transforming growth factor β (TGFβ) expression in a type 1 diabetes mellitus diabetic nephropathy mouse model. Through cellular and animal experiments, we observed that PJ-34 significantly enhanced the proliferative capacity of cells damaged by high glucose, reduced apoptosis, and decreased the release of proinflammatory factors TGFα, interleukin-6, and interleukin-1β.
View Article and Find Full Text PDFCharacterization and comparison of immunity against MPXV for individuals infected with MPXV or vaccinated with modified vaccinia Ankara vaccines.
J Immunol
February 2025
Vaccine Research Institute, Université Paris-Est Créteil, Créteil, France.
The 2022 Mpox virus (MPXV) outbreak revitalized questions about immunity against MPXV and vaccinia-based vaccines (VAC-V), but studies are limited. We analyzed immunity against MPXV in individuals infected with MPXV or vaccinated with the licensed modified vaccinia Ankara (MVA) Bavarian Nordic or an experimental MVA-HIVB vaccine. The frequency of neutralizing antibody responders was higher among MPXV-infected individuals than MVA vaccinees.
View Article and Find Full Text PDFModulating inhibitory synaptic plasticity to restore basal ganglia dynamics in Parkinson's disease.
Brain
March 2025
Krembil Brain Institute, University Health Network, Toronto, ON M5T 1M8, Canada.
Parkinson's disease is characterized, in part, by hypoactivity of direct pathway inhibitory projections from striatum to the globus pallidus internus (GPi) and indirect pathway inhibitory projections from globus pallidus externus (GPe) to the subthalamic nucleus (STN). In people with Parkinson's disease (n=32), we explored the potential use of intracranial stimulation for eliciting long-term potentiation (LTP) of these underactive pathways to produce improvement of symptoms that persists beyond stimulation cessation. During GPi deep brain stimulation (DBS) surgery, we found strong evidence (p<.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!